Atara Biotherapeutics Inc. (NASDAQ:ATRA)’s share price traded up 7.3% on Tuesday . The stock traded as high as $20.57 and last traded at $20.57, with a volume of 108,066 shares trading hands. The stock had previously closed at $19.17.

Several equities analysts have recently weighed in on the company. JMP Securities reiterated a “buy” rating on shares of Atara Biotherapeutics in a research report on Saturday, July 9th. Zacks Investment Research upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 2nd. Canaccord Genuity reissued a “buy” rating on shares of Atara Biotherapeutics in a research note on Tuesday, June 7th. Jefferies Group reissued a “buy” rating and set a $25.00 price objective on shares of Atara Biotherapeutics in a research note on Tuesday, August 9th. Finally, Goldman Sachs Group Inc. lowered Atara Biotherapeutics from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $23.00 to $16.00 in a research note on Thursday, September 15th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $26.14.

The stock’s market capitalization is $586.30 million. The stock has a 50 day moving average of $21.26 and a 200 day moving average of $20.02.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.05. On average, equities research analysts forecast that Atara Biotherapeutics Inc. will post ($2.85) EPS for the current year.

In other news, CEO Isaac E. Ciechanover sold 7,200 shares of the company’s stock in a transaction on Friday, September 16th. The stock was sold at an average price of $19.36, for a total value of $139,392.00. Following the completion of the sale, the chief executive officer now directly owns 229,136 shares in the company, valued at approximately $4,436,072.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Christopher Haqq sold 1,346 shares of the company’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $22.32, for a total value of $30,042.72. Following the completion of the sale, the insider now owns 295,294 shares of the company’s stock, valued at $6,590,962.08. The disclosure for this sale can be found here. Insiders own 16.10% of the company’s stock.

Large investors have recently bought and sold shares of the company. BlackRock Group LTD raised its stake in Atara Biotherapeutics by 76.8% in the first quarter. BlackRock Group LTD now owns 5,400 shares of the company’s stock valued at $103,000 after buying an additional 2,345 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Atara Biotherapeutics by 3.1% in the first quarter. JPMorgan Chase & Co. now owns 62,600 shares of the company’s stock worth $1,191,000 after buying an additional 1,900 shares during the last quarter. RTW Investments LLC raised its stake in shares of Atara Biotherapeutics by 11.1% in the first quarter. RTW Investments LLC now owns 473,126 shares of the company’s stock worth $9,004,000 after buying an additional 47,274 shares during the last quarter. A.R.T. Advisors LLC raised its stake in shares of Atara Biotherapeutics by 79.6% in the first quarter. A.R.T. Advisors LLC now owns 63,941 shares of the company’s stock worth $1,216,000 after buying an additional 28,330 shares during the last quarter. Finally, Bridger Management LLC acquired a new stake in shares of Atara Biotherapeutics during the first quarter worth about $14,072,000. Hedge funds and other institutional investors own 75.50% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.